exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087986 RNA Name: hsa-miR-296-3p RNA Type: miRNA Chromosome: chr20 Starnd: - Coordinate: Start Site(bp): 58817626 End Site(bp): 58817647 External Links: hsa-miR-296-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ATXN7 chr3 63864557 64003462 + BAZ2A chr12 56595596 56636816 - COL6A1 chr21 45981769 46005050 + CYLD chr16 50742050 50801935 + FAM210A chr18 13663347 13726663 - HMGCS1 chr5 43287470 43313512 - HOXC10 chr12 53985065 53990279 + HP1BP3 chr1 20740266 20787323 - KAT6A chr8 41929479 42051994 - KMT2D chr12 49018975 49059774 - KPNA6 chr1 32108056 32176563 + LASP1 chr17 38869859 38921770 + MINK1 chr17 4833340 4898061 + NFAT5 chr16 69565094 69704666 + PFN2 chr3 149964904 150050788 - RTKN chr2 74425835 74442422 - SERF2 chr15 43777087 43802589 + SLC2A4RG chr20 63739776 63744050 + STK35 chr20 2101827 2177038 + TMEM97 chr17 28319200 28328685 + TP53 chr17 7661779 7687550 - TULP3 chr12 2877223 2941138 + UBA2 chr19 34428352 34471251 + VANGL1 chr1 115641970 115698224 + ZFP91 chr11 58579063 58621550 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001867 chr9 86294689 86297981 - hsa_circ_0001866 chr9 86293355 86297981 - hsa_circ_0001046 chr2 97024782 97033111 + hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009133.5 chr16 29808679 29812227 + AC016831.1 chr7 130876809 130913310 - AC023509.1 chr12 53441741 53467528 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - PCBP2-OT1 chr12 53464468 53465057 + SNHG25 chr17 64145970 64146476 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.